Hanmi制药公司揭幕了HM17321, 这是一种新的肥胖治疗, 刺激脂肪减退和瘦肌肉。 Hanmi Pharmaceuticals unveiled HM17321, a new obesity treatment that boosts fat loss and lean muscle.

Hanmi制药公司引进了HM17321, 这是一种新颖的肥胖治疗方法,它提倡减肥,同时增加瘦肌肉质量,解决当前GLP-1疗法的一个共同问题,可能导致肌肉丧失。 Hanmi Pharmaceuticals has introduced HM17321, a novel obesity treatment that promotes fat loss while enhancing lean muscle mass, addressing a common issue with current GLP-1 therapies that can lead to muscle loss. 针对CRF2受体,HM17321显示出作为一个具有成本效益的替代品的潜力,可以单独或与其他治疗一起用于改善减肥结果. Targeting the CRF2 receptor, HM17321 shows potential as a cost-effective alternative and can be used alone or with other treatments to improve weight loss outcomes. 药物的有前途的结果在2024年肥胖周会议上分享. The drug's promising results were shared at the 2024 ObesityWeek conference.

November 06, 2024

5 文章